RCC With NF2 Mutations Associated With Metastatic Disease, Poor Survival
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.
Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.
Patients hospitalized with COVID-19 receiving supplemental oxygen had similar mortality outcomes with high- vs standard-dose dexamethasone, but evidence suggests higher dexamethasone doses may be associated with adverse outcomes. These study results were presented at IDWeek 2022, held from October 19 to 23, in Washington, DC. Anti-inflammatory agents, such as dexamethasone, are standard treatment for COVID-19…
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
The cancer incidence in certain immunocompromised patients was almost twice as high as the age-adjusted cancer incidence in the general population.
There was no significant difference in post-infusion hospitalizations between patients with and without a history of cancer.
Patients with perineural invasion had a 4-fold higher risk of biochemical recurrence.